Real-World Perspectives in Managing CLL Treatment
Support for this activity has been provided through educational grants from AbbVie Inc. and AstraZeneca Pharmaceuticals. Estimated time to complete: 0.75 hours Management op tions for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings — though of course beneficial for CLL patients — represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of